Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
ABBV-400 by AbbVie for Uterine Cancer: Likelihood of Approval
ABBV-400 is under clinical development by AbbVie and currently in Phase I for Uterine Cancer. According to GlobalData, Phase I...
ABBV-400 by AbbVie for Melanoma: Likelihood of Approval
ABBV-400 is under clinical development by AbbVie and currently in Phase I for Melanoma. According to GlobalData, Phase I drugs...
Venetoclax by AbbVie for Transformed Mycosis Fungoides: Likelihood of Approval
Venetoclax is under clinical development by AbbVie and currently in Phase II for Transformed Mycosis Fungoides. According to GlobalData, Phase...
Venetoclax by AbbVie for Peripheral T-Cell Lymphomas (PTCL): Likelihood of Approval
Venetoclax is under clinical development by AbbVie and currently in Phase II for Peripheral T-Cell Lymphomas (PTCL). According to GlobalData,...
Elsubrutinib by AbbVie for Systemic Lupus Erythematosus: Likelihood of Approval
Elsubrutinib is under clinical development by AbbVie and currently in Phase II for Systemic Lupus Erythematosus. According to GlobalData, Phase...
Upadacitinib ER by AbbVie for Systemic Lupus Erythematosus: Likelihood of Approval
Upadacitinib ER is under clinical development by AbbVie and currently in Phase III for Systemic Lupus Erythematosus. According to GlobalData,...
AGN-193408 SR by AbbVie for Open-Angle Glaucoma: Likelihood of Approval
AGN-193408 SR is under clinical development by AbbVie and currently in Phase II for Open-Angle Glaucoma. According to GlobalData, Phase...
AGN-193408 SR by AbbVie for Ocular Hypertension: Likelihood of Approval
AGN-193408 SR is under clinical development by AbbVie and currently in Phase II for Ocular Hypertension. According to GlobalData, Phase...
Serclutamab talirine by AbbVie for Glioblastoma Multiforme (GBM): Likelihood of Approval
Serclutamab talirine is under clinical development by AbbVie and currently in Phase I for Glioblastoma Multiforme (GBM). According to GlobalData,...
Lemzoparlimab by AbbVie for Epithelial Ovarian Cancer: Likelihood of Approval
Lemzoparlimab is under clinical development by AbbVie and currently in Phase II for Epithelial Ovarian Cancer. According to GlobalData, Phase...
Lemzoparlimab by AbbVie for Peritoneal Cancer: Likelihood of Approval
Lemzoparlimab is under clinical development by AbbVie and currently in Phase II for Peritoneal Cancer. According to GlobalData, Phase II...
Lemzoparlimab by AbbVie for Non-Small Cell Lung Carcinoma: Likelihood of Approval
Lemzoparlimab is under clinical development by AbbVie and currently in Phase II for Non-Small Cell Lung Carcinoma. According to GlobalData,...
Lemzoparlimab by AbbVie for Fallopian Tube Cancer: Likelihood of Approval
Lemzoparlimab is under clinical development by AbbVie and currently in Phase II for Fallopian Tube Cancer. According to GlobalData, Phase...
Lemzoparlimab by AbbVie for Primary Mediastinal B-Cell Lymphoma: Likelihood of Approval
Lemzoparlimab is under clinical development by AbbVie and currently in Phase II for Primary Mediastinal B-Cell Lymphoma. According to GlobalData,...
ABBV-744 by AbbVie for Myelofibrosis: Likelihood of Approval
ABBV-744 is under clinical development by AbbVie and currently in Phase II for Myelofibrosis. According to GlobalData, Phase II drugs...
ABBV-744 by AbbVie for Post-Polycythemia Vera Myelofibrosis (PPV-MF): Likelihood of Approval
ABBV-744 is under clinical development by AbbVie and currently in Phase II for Post-Polycythemia Vera Myelofibrosis (PPV-MF). According to GlobalData,...
Budigalimab by AbbVie for Human Immunodeficiency Virus (HIV) Infections (AIDS): Likelihood of Approval
Budigalimab is under clinical development by AbbVie and currently in Phase II for Human Immunodeficiency Virus (HIV) Infections (AIDS). According...
Risk adjusted net present value: What is the current valuation of AbbVie's ABBV-668?
ABBV-668 is a small molecule commercialized by AbbVie, with a leading Phase II program in Ulcerative Colitis. According to Globaldata,...
Risk adjusted net present value: What is the current valuation of AbbVie's Telisotuzumab Vedotin?
Telisotuzumab Vedotin is a monoclonal antibody conjugated commercialized by AbbVie, with a leading Phase III program in Non-Small Cell Lung...
Elsubrutinib by AbbVie for Systemic Lupus Erythematosus: Likelihood of Approval
Elsubrutinib is under clinical development by AbbVie and currently in Phase II for Systemic Lupus Erythematosus. According to GlobalData, Phase...